ArticleFrontiers in cardiovascular medicine2025
Lactate to albumin ratio as a prognostic marker for all-cause mortality in patients with venous thromboembolism: a retrospective cohort study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactate to albumin ratio LAR predicts mortality in critically ill adults with asthma across two cohorts.Scientific reports · 2026Article
- Developing and validating a lactate-to-albumin ratio-enhanced score for mortality prediction in ICU patients with acute pulmonary embolism: a multi-cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The lactate to albumin ratio (LAR) may serve as a prognostic marker. This study evaluated its association with clinical outcomes in patients with venous thromboembolism (VTE). Methods: We performed a retrospective cohort analysis using data from the MIMIC-IV 3.1 database, including 4,181 patients diagnosed with VTE. The primary outcomes were 30-day and 365-day all-cause mortality. Cox proportional hazards models assessed the relationship between LAR and mortality. Restricted cubic spline (RCS) analysis examined the non-linear relationship. Kaplan-Meier (KM) survival curves were generated to compare outcomes across the LAR groups. Results: Among the 1,992 patients included in the study, mortality rates at 30 and 365 days were 19.58% and 22.69%, respectively. Elevated LAR levels were significantly associated with increased mortality at both time points ( Conclusions: Elevated LAR is significantly associated with increased mortality in VTE patients. LAR can be used as a potential indicator for assessing the short-and long-term risk of mortality in such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.